$1,000 follows their calls into $804
Jonathan Faison@jfais20$VSTM - nice delayed reaction, market digesting the offering & realizing the tolerability & efficacy edge in G12D vs $RVMD daraxonrasib is real (or at least the possibility of it being real merits a rerating) + CRC optionality
Jonathan Faison@jfais20$OMER (L) This stuff is too crazy to make up... the 8-member expert group (including two transplant physicians) Recommends review of patient-level data to better understand factors associated with treatment response and survival Omeros submits said data for Yartemlea to CHMP
Jonathan Faison@jfais20I agree with Chuck $XBI
Jonathan Faison@jfais20$VSTM - nice delayed reaction, market digesting the offering & realizing the tolerability & efficacy edge in G12D vs $RVMD daraxonrasib is real (or at least the possibility of it being real merits a rerating) + CRC optionality
Jonathan Faison@jfais20$OMER - reminder for the "drug doesn't work" crowd $AZN (SoC is changing for a reason)
Jonathan Faison@jfais20$OMER (L) On Monday, thesis strengthened for Omeros after HSCT-TMA competitor AstraZeneca (AZN) reported that a phase 3 trial failed to achieve statistical significance on the primary endpoint of event-free survival in patients aged 12 or older. AstraZeneca is still moving
